Pages

Friday, January 18, 2019

Tom Marino Bolts From Congress!

Tom Marino quits three weeks after being sworn in.
Tom Marino decided to pack it up. The four term lawmaker decided to quit to return to private sector.

That puts his seat up for a special election and a political fight.

The Republican lawmaker decides to quit after three weeks on the job. This is the latest nonsense that the junk food media refuse to cover. They're too busy worrying about comments made by Rep. Rashida Tlaib (D-MI), Rep. Ilhan Omar (D-MN) and Rep. Alexandria Ocasio-Cortez (D-NY).

The Republicans aren't concerned about the government shutdown.

Speak of that. Donald J. Trump will make an announcement on Saturday. It is likely he will declare a national emergency and force our military to fund the border wall. That will be a legal challenge and a risky move.

After being elected on November 6, 2018 to a fifth term to the Pennsylvania 12th Congressional district, Marino announced his resignation from the U.S. House of Representatives on January 17, 2019.

Marino's resignation is effective January 23, 2019. After Pennsylvania's congressional districts were redrawn in 2018, he won re-election with 66% of his district's votes, defeating Democrat Marc Friedenberg.

Marino described his decision to resign as follows: "Having spent over two decades serving the public, I have chosen to take a position in the private sector where I can use both my legal and business experience to create jobs around the nation."

Marino's resignation requires a special election by Gov. Tom Wolf, who must issue a writ of election within 10 days of Marino's resignation becoming effective on January 23, 2019. Per Pennsylvania law, a special election must then occur no fewer than 60 days following the gubernatorial proclamation being made.

He was an early Trump supporter among congressional Republicans. He was nominated to be the president's Drug Czar but withdrew after a joint CBS "60 Minutes" and Washington Post report revealed he took nearly $100,000 from pharmaceutical lobbyists.



No comments:

Post a Comment